Wiseguyreports.Com Publish New Report On-“Small Molecule API 2017 Global Industry – Key Players, Size, Trends, Outlook, Growth (CAGR of 7%) - Analysis to 2022”.

PUNE, INDIA, October 10, 2017 /EINPresswire.com/ --

Small Molecule API Market 2017

The global small molecule API market was valued at $ 132,877.3 million in 2016 and expected to reach $ 279,687.1 million by 2027 at a CAGR of 7% during the forecast period.

The major factors responsible for the growth of global Small molecule API market are growing demand for newly developed small molecules drugs, growing trend of outsourcing and growing pharmaceutical industry in developing nations. The growth barriers are and austerity measures in Europe among others.

The market is majorly categorized on the basis of types which is further segmented into synthetic/chemical API and biological API. On the basis of application the market is segmented into cardiovascular, oncology, diabetes and immunological disorders. On the basis of manufacturing methods the market is segmented into in-house manufacturing and contract manufacturing and geographic regions.

Globally, North America holds the largest market share of global small molecule API market, registering 38.84 % in 2016.

The scope of global small molecule API market study includes the market value, market size and a detailed analysis of vendor products and strategies.


Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1292097-global-small-molecule-api-market-estimation-forecast-2013-2027


Key Players
The leading players of the global small molecule API market are Albemarle Corporation, Allergan Plc, Aurobindo Pharma, Cambrex Corporation, Dr. Reddy’s laboratories ltd., Glaxosmithkline Plc, Lonza , Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., Novartis AG, Siegfried AG , Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and others.

Target Audience
• Small molecule API companies
• Raw Material Suppliers
• Key executive (CEO and COO) and strategy growth manager


Key Findings
• On the basis of types, synthetic/chemical API accounted for the largest market share of 81.31 % in 2016.
• US accounted for the largest market share of 59.75 % in 2016, with a market value of USD 30,848.3 million and is projected to grow at a CAGR of 6.6 % during the forecast period.

Key Regions
Americas
Europe
Asia– Pacific
Rest of the World



Any Query, Submit Here @ https://www.wiseguyreports.com/enquiry/1292097-global-small-molecule-api-market-estimation-forecast-2013-2027


Table of Contents –Analysis of Key Points

1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 MARKET DYNAMICS
4 MARKET FACTOR ANALYSIS
5 GLOBAL SMALL MOLECULES API, BY TYPE
6 GLOBAL SMALL MOLECULE API MARKET, BY APPLICATION
7 GLOBAL SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS
8 GLOBAL SMALL MOLECULE API MARKET, BY REGION
9 COMPETITIVE LANDSCAPE

10 COMPANY PROFILE
10.1 ALBEMARLE CORPORATION
10.1.1 OVERVIEW 80
10.1.2 PRODUCT OVERVIEW 80
10.1.3 FINANCIALS 81
10.1.4 KEY DEVELOPMENTS 81
10.2 ALLERGAN PLC
10.2.1 OVERVIEW 82
10.2.2 PRODUCT OVERVIEW 82
10.2.3 FINANCIALS 83
10.2.4 KEY DEVELOPMENTS 83
10.3 AUROBINDO PHARMA
10.3.1 OVERVIEW 84
10.3.2 PRODUCT OVERVIEW 84
10.3.3 FINANCIALS 85
10.3.4 STRATEGY 85
10.3.5 KEY DEVELOPMENT 85
10.4 CAMBREX CORPORATION
10.4.1 OVERVIEW 86
10.4.2 PRODUCT OVERVIEW 86
10.4.3 FINANCIALS 87
10.4.4 KEY DEVELOPMENTS 87
10.5 DR. REDDY’S LABORATORIES LTD.
10.5.1 OVERVIEW 88
10.5.2 PRODUCT OVERVIEW 88
10.5.3 FINANCIALS 89
10.5.4 KEY DEVELOPMENTS 89
10.6 GLAXOSMITHKLINE PLC
10.6.1 OVERVIEW 90
10.6.2 PRODUCT OVERVIEW 90
10.6.3 FINANCIALS 91
10.6.4 STRATEGY 91
10.6.5 KEY DEVELOPMENTS 92
10.7 LONZA 92
10.7.1 OVERVIEW 92
10.7.2 PRODUCT OVERVIEW 92
10.7.3 FINANCIALS 93
10.7.4 STRATEGY 93
10.7.5 KEY DEVELOPMENTS 94
10.8 MERCK SHARP & DOHME CORP.
10.8.1 OVERVIEW 94
10.8.2 PRODUCT OVERVIEW 95
10.8.3 FINANCIAL 95
10.8.4 KEY DEVELOPMENTS 96
10.9 MYLAN N.V.
10.9.1 OVERVIEW 96
10.9.2 PRODUCT OVERVIEW 97
10.9.3 FINANCIALS 97
10.9.4 KEY DEVELOPMENTS 98
..…..Continued

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here